|
|
|
| Effect of Pivastatin Combined with Trimetazidine on Neuroendocrine Factor and Cardiac Function in Patients with Chronic Heart Failure |
| TAN De-sheng, CAO Gang, XU Qiang,et al |
| Shaoguan Railway Hospital,Shaoguan Guangdong 512023 |
|
|
|
|
Abstract 【Objective】To analyze the effects of Pivastatin combined with Trimetazidine on neuroendocrine factors and cardiac function in patients with chronic heart failure. 【Methods】One hundred and thirty-six patients with chronic heart failure admitted to our hospital were divided into observation group (trimetazidine + pitavastatin, n=70) and control group (trimetazidine, n=66) according to different medications. The cardiac function indexes [left ventricular end systolic diameter (LVESD), left ventricular end diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF)], 6-minute walking test, plasma levels of neuroendocrine factors [plasma atrial natriuretic peptide (ANP), plasma brain natriuretic peptide (BNP), plasma endothelin (ET)] were compared between the two groups before and after treatment. 【Results】After treatment, the LVEDD and LVESD of the two groups were lower than before treatment, and the LVEF was higher than before treatment, and the difference between the two groups was statistically significant (P<0.05). After treatment, the 6-minute walking distance of the observation group and the control group was greater than that before treatment, and the observation group was larger than that of the control group, the difference was statistically significant (P<0.05). After treatment, the levels of plasma ANP, BNP and ET in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05).【Conclusion】Pivastatin combined with trimetazidine can effectively inhibit the overactivation of neuroendocrine system and reverse ventricular remodeling in patients with chronic heart failure. It has a good effect and is worthy of clinical application.
|
|
Received: 15 April 2019
|
|
|
|
|
|
[1] 汪丽丽,贺钰梅,郝春举,等.瑞舒伐他汀联合辅酶Q10治疗慢性心衰后血清炎性指标、血清脑钠肽及心功能的变化[J].中国医药导报,2016,13(6):166-169.
[2] 中华医学会心血管病学分会. 中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志, 2018, 46(10):760-789.
[3] 许彦倩, 严炜. 阿托伐他汀联合曲美他嗪对老年冠心病左心功能不全患者心功能、炎性因子和血管内皮功能的影响[J].中国老年学杂志, 2017, 37(20):5050-5052.
[4] 周全魁.辛伐他汀联合曲美他嗪治疗老年慢性心力衰竭患者的疗效和安全性[J].中国老年学杂志, 2015, 35(8):2240-2241.
[5] 杜锦权, 周俊阁, 孟志刚,等. 阿托伐他汀联合曲美他嗪治疗对慢性心力衰竭患者心功能和细胞因子的影响[J].海南医学院学报, 2015, 21(5):621-623.
[6] Shah SJ, Kitzman DW, Borlaug BA,et al.Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap[J].Circulation,2016, 134(1):73-90.
[7] 张勤仓,马新萍.卡维地洛对老年慢性心衰患者神经内分泌激素激活、血管内皮功能及糖脂代谢的影响[J].海南医学院学报,2015,21(7):914-916.
[8] Ky B, Kimmel SE, Safa RN,et al.Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure[J].Circulation,2016, 120(4):310-317. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2019, 36(6): 1216-1217. |
|
|
|
|
2019, Vol. 36 
